Astellas Pharma(ALPMF)
$16.55+0.59 (+3.70%)
ALPMF
Astellas Pharma stock forecast
$16.55
At close:+0.59 (+3.70%)
Astellas Pharma (ALPMF) Stock Forecast & Price Target
58 Followers
ALPMF Analyst Ratings
Hold
2Buy3Hold1Sell
Based on 6 analysts giving stock ratings to Astellas Pharma in the past 3 months
ALPMF Stock 12 Month Forecast
Average Price Target
$15.74▼(-4.89% Downside)Based on 6 Wall Street analysts offering 12 month price targets for Astellas Pharma in the last 3 months. The average price target is $15.74 with a high forecast of $18.78 and a low forecast of $12.52. The average price target represents a -4.89% change from the last price of $16.55.
Past 12 Months12 Month ForecastJan2026Oct2026
High$18.78
Average$15.74
Low$12.52
Highest Price TargetHighest$18.78Average Price Target$15.74Lowest Price TargetLowest$12.52
Detailed List of Analyst Forecasts
Analyst Type
Ranks
Analyst Rating
Upside/ Downside
Action
| Price Target | Article | |||||||
|---|---|---|---|---|---|---|---|---|
 Unknown AnalystNot Ranked | Morgan Stanley | $13.77→$14.08 | hold | -14.91%Downside | Reiterated | 11/05/26 | ||
| Unknown AnalystNot Ranked | Macquarie | $16.90→$18.15 | buy | 9.67%Upside | Reiterated | 11/05/26 | ||
| Unknown AnalystNot Ranked | Daiwa | $10.64→$12.52 | sell | -24.36%Downside | Reiterated | 09/30/26 | ||
| Unknown AnalystNot Ranked | Mizuho Securities | $15.27 | hold | -7.72%Downside | Reiterated | 09/14/26 | ||
| Unknown AnalystNot Ranked | CLSA | $18.78 | buy | 13.45%Upside | Reiterated | 08/18/26 | ||
| Unknown AnalystNot Ranked | J.P. Morgan | $14.40→$15.65 | hold | -5.46%Downside | Reiterated | 08/17/26 | ||
| Hidemaru Yamaguchi | Citi | $15.46 | hold | -6.59%Downside | Reiterated | 08/07/26 | ||
| Unknown AnalystNot Ranked | Goldman Sachs | $18.78→$19.40 | buy | 17.24%Upside | Reiterated | 08/06/26 | ||
| Unknown AnalystNot Ranked | SBI Securities | $14.15 | hold | -14.53%Downside | Reiterated | 07/29/26 | ||
| Unknown AnalystNot Ranked | UBS | $15.02→$14.40 | hold | -13.02%Downside | Reiterated | 07/15/26 | ||
| Miki Sogi | Bernstein | $13.77 | hold | -16.80%Downside | Reiterated | 07/07/26 | ||
| Unknown AnalystNot Ranked | Bank of America Securities | $16.90 | buy | 2.11%Upside | Reiterated | 06/05/26 | ||
| Stephen Barker | Jefferies | $17.52 | buy | 5.89%Upside | Reiterated | 03/24/26 | ||
| Unknown AnalystNot Ranked | Nomura | $15.02→$15.65 | hold | -5.46%Downside | Downgraded | 02/19/26 | ||
| Unknown AnalystNot Ranked | SMBC Nikko | $10.64→$12.52 | hold | -24.36%Downside | Reiterated | 02/16/26 |
| Rating | Article | ||||
|---|---|---|---|---|---|
| Unknown AnalystMorgan StanleyNot Ranked | HoldReiterated$13.77→$14.08 | 11/05/26 | -14.91%Downside | ||
| Unknown AnalystMacquarieNot Ranked | BuyReiterated$16.90→$18.15 | 11/05/26 | 9.67%Upside | ||
| Unknown AnalystDaiwaNot Ranked | SellReiterated$10.64→$12.52 | 09/30/26 | -24.36%Downside | ||
| Unknown AnalystMizuho SecuritiesNot Ranked | HoldReiterated$15.27 | 09/14/26 | -7.72%Downside | ||
| Unknown AnalystCLSANot Ranked | BuyReiterated$18.78 | 08/18/26 | 13.45%Upside | ||
| Unknown AnalystJ.P. MorganNot Ranked | HoldReiterated$14.40→$15.65 | 08/17/26 | -5.46%Downside | ||
| Hidemaru YamaguchiCiti | HoldReiterated$15.46 | 08/07/26 | -6.59%Downside | ||
| Unknown AnalystGoldman SachsNot Ranked | BuyReiterated$18.78→$19.40 | 08/06/26 | 17.24%Upside | ||
| Unknown AnalystSBI SecuritiesNot Ranked | HoldReiterated$14.15 | 07/29/26 | -14.53%Downside | ||
| Unknown AnalystUBSNot Ranked | HoldReiterated$15.02→$14.40 | 07/15/26 | -13.02%Downside | ||
| Miki SogiBernstein | HoldReiterated$13.77 | 07/07/26 | -16.80%Downside | ||
| Unknown AnalystBank of America SecuritiesNot Ranked | BuyReiterated$16.90 | 06/05/26 | 2.11%Upside | ||
| Stephen BarkerJefferies | BuyReiterated$17.52 | 03/24/26 | 5.89%Upside | ||
| Unknown AnalystNomuraNot Ranked | HoldDowngraded$15.02→$15.65 | 02/19/26 | -5.46%Downside | ||
| Unknown AnalystSMBC NikkoNot Ranked | HoldReiterated$10.64→$12.52 | 02/16/26 | -24.36%Downside |
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Best Analysts Covering Astellas Pharma
3 Months
Success Rate2/3 ratings generated profit
67%
Average Return
+2.27%
Copying OpenAI Drug Manufacturers - General's trades and holding each position for 3 Months would result in 66.67% of your transactions generating a profit, with an average return of +2.27% per trade.
1 Year
Success Rate2/2 ratings generated profit
100%
Average Return
+15.55%
Copying xAi Drug Manufacturers - General's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +15.55% per trade.
2 Years
Success Rate2/2 ratings generated profit
100%
Average Return
+15.55%
Copying xAi Drug Manufacturers - General's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +15.55% per trade.
ALPMF Analyst Recommendation Trends
| Rating | Jul 26 | Aug 26 | Sep 26 | Oct 26 | Nov 26 |
|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 |
| Buy | 3 | 4 | 3 | 3 | 2 |
| Hold | 8 | 8 | 7 | 4 | 2 |
| Sell | 1 | 1 | 2 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| total | 12 | 13 | 12 | 8 | 5 |
In the current month, ALPMF has received 2 Buy Ratings, 2 Hold Ratings, and 1 Sell Ratings. ALPMF average Analyst price target in the past 3 months is 15.74.
ALPMF Financial Forecast
High$0.44
Consensus$0.38
Low$0.32
ALPMF Earnings Forecast
Next quarter’s earnings estimate for ALPMF is $0.38 with a range of $0.32 to $0.44. The previous quarter’s EPS was $0.35. Its overall industry beat the EPS estimate 57.80% of the time in the past 12 months.
High$4.11B
Consensus$3.88B
Low$3.67B
ALPMF Sales Forecast
Next quarter’s sales forecast for ALPMF is $3.88B with a range of $3.67B to $4.11B. The previous quarter’s sales results were $3.99B. Its overall industry beat sales estimates 50.04% of the time in the past 12 months.
ALPMF Stock Forecast FAQ
What is ALPMF’s average 12-month price target, according to analysts?
Based on analyst ratings, Astellas Pharma’s 12-month average price target is $15.74.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is ALPMF a Buy, Sell or Hold?
Astellas Pharma has a consensus rating of Hold which is based on 2 buy ratings, 3 hold ratings and 1 sell ratings.
What is Astellas Pharma’s price target?
The average price target for Astellas Pharma is $15.74. This is based on 6 12-month price targets, issued in the past 3 months. The highest analyst price target is $18.78, the lowest forecast is $12.52. The average price target represents a 4.89% decrease from the current price of $16.55.
What do analysts say about Astellas Pharma?
Astellas Pharma’s analyst rating consensus is a Hold. This is based on the ratings of 6 Wall Street analysts.
How can I buy shares of ALPMF?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
